Introduction
Chondromyxoid fibroma (CMF) is a slowly growing, benign bone tumor that is exceedingly rare within the temporal bone.
1 Our review of the literature identified only 6 previously reported cases of CMF within the mastoid bone.!" We report a new case of CMF of the mastoid portion of the temporal bone, and we discuss the correlation between the histologic features and findings on magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT).
Case report
A 38-year-old woman presented to Beth Israel Hospital in New York City with a 3-month history of left-sided hearingloss.Physicalexamination revealed an erythematous left external auditory canal and bulging posterior wall. The bulging had caused about an 80% occlusion of the canal.
MRI of the brain revealed a destructive 4.l-cm mass within the left mastoid bone ( figure 1, A) . The signal of the mastoid was predominantly isointense with that of the skeletal muscle. Scattered areas of hypointense signal were seen on T l-weighted imaging, and scattered areas of hyperintense signal were seen on T2 weighting. Following the administration of intravenous contrast, the mass demonstrated peripheral enhancement. There was no MRI evidence of intracranial extension or dural involvement.
Corresponding to the mass that had been identified on MRI, PET/CT revealed an expansile, destructive mass within the left mastoid that demonstrated hypermetabolism (standardized uptake value [SUVj: 5.9) and resulted in a mass effect ( figure 1, B) .
The patient was taken to the operating room for a transmastoid biopsy and subsequent tumor resection. The tumor was noted to be located extradurally. Frozensection histologic examination identified the biopsy specimen as a low-grade fibrocartilaginous neoplasm consistent with a CMF (figure 2). The tumor was resected via a postauricular infratemporal fossa approach. Complete resection was achieved with skeletonization of the facial nerve and decompression of the sigmoid sinus and jugular bulb along with control of the lower cranial nerves. This necessitateda sacrifice ofconductive hearing via the removal of the middle ear structures and the tympanic bone for control of these neurovascular structures.
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On postoperative follow-up examination, the patient had persistent conductive hearing loss secondary to the ear canal closure that had been performed during surgery. She was scheduled to undergo bone-anchored hearing aid implantation to restore her hearing. She did not experience any vertigo, and she has been followed for 4 years without recurrence. 
Discussion
CMF is characterized by chondral, myxoid, and fibrous differentiation. The tumor arises from the cartilage-forming connective tissue of the bone marrow space, usuallyin the metaphysis ofthe long bones, especially the tibia, fibula, and foot bones; patients with CMF in these typical locations .are generally younger-that is, in the second or third decade of life Less common locations for CMF include the bone surfaces of the skull base, sternum, spine, and paranasal sinuses; patients with CMF in these unusual locations typically present in the fourth decade of life.":" Our patient was 38 years old. CMF of the skull is believed to most often arise from the synostosis at the base of the skull or from skull sutures.'
Patients with CMF in the long bones complain primarily of pain and soft-tissue swelling. The onset of symptoms of skull base CMF are more insidious; they can include hearing loss, otalgia, and dizziness/vertigo. One case of facial nerve paralysis as a result of a large CMF within the petrous apex has been reported; that tumor extended into the posterior fossa and the jugular foramen.' Diagnosis. A confident diagnosis of CMF based on imaging alone may be difficult because of the rarity of this tumor. A biopsy analysis is necessary to establish a definitive diagnosis. Imaging is important in planning surgical intervention. CT allows for identification ofthe tumor's origin and can show matrix calcification.v-'-" Matrix calcification is more common in CMF of the skull than in CMF ofthe long bones." The relationship of the tumor to the adjacent bony structures is best delineated by high-resolution CT. The bone cortex is usually thin and expanded by the tumor.
MRI is superior to CT in its power to demonstrate the extent of the disease. CMFs typically display a hy-202 " www.entjournal.com pointense signal on Tl-weighted MRI and a heterogeneous hyperintense signal on T2-weighted imaging. T2 heterogeneity is attributable to the varying chondroid, myxoid, and fibrous elements. These lesions usually enhance intensely with gadolinium contrast. 13 Differential diagnosis. Differentiating a CMF from other diagnostic considerations in patients with a chondroid lesion of the skull base remains a challenge. The main differential diagnoses include chordoma and chondrosarcoma with myxoid features.
Chordoma. A CMF can be distinguished from a chordoma anatomicallyand by immunohistochemistry. Chordomas usually arise from the clivus with associated extraosseous extension, and they are more bonedestructive. On Tl-weighted MRI, chordomas usually demonstrate an intermediate signal with some areas of low signal representing mucus. On T2-weighted MRI, they generally show a high signal. They may demonstrate moderate or mixed enhancement. On histology, chordomas usually express epithelial antigens such as keratin and epithelial membrane antigen, whereas CMFs do not."
Chondrosarcoma. Differentiating a CMF from a chondrosarcoma can be difficult. The MRI characteristics of both are similar to those of chordomas, as they are all bright on T2 weighting. Moreover, both CMFs and chondrosarcomas express vimentin and 5-100 protein on Immunohistochemistry," A chondrosarcoma may exhibit a permeative growth pattern as the tumor encases preexisting bony trabeculae and becomes more high-grade on light microscopy," Other considerations. It can be difficult to differentiate a chondromyxomalike or chondroblastic variant of low-grade osteosarcoma from CMF on a biopsy because these types ofosteosarcoma have very large CMF -Iike areas. However, the diagnostic hallmark of osteosarcoma is the presence of osteoid production, which is absent from CMFsY Another clear diagnostic indicator is the presence of mitoses and nuclear atypia, which are seen in osteosarcoma but not in CMF.
Other diagnostic considerations for destructive lesions in the mastoid include endolymphatic sac tumors and contiguous lesions from nasopharyngeal carcinoma and paragangliomas." These lesions can often be ruled out on the basis of their imaging characteristics. Paragangliomas typically show isointense signal to skeletal structures; dark Signal areas represent flow voids on T 1-weighted MRI (salt-and-pepper appearance). The underlying hypervascularity of the tumor results in homogeneous and intense enhancement following the administration ofintravenous contrast." Endolymphatic sac tumors are aggressive papillary tumors; most are erosive expansile masses that demonstrate calcifications on CT and flow voids on MRL
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Treatment. The preferred treatment for patients with CMF is en bloc resection; curettage can be performed as an alternative if necessary. Radiation therapy is contraindicated because of the risk ofinducing malignancy. Periodic follow-up is indicated in view of the fact that CMF frequently recurs after surgery because it is often not completely excised. 4 ,13,16,17 Most recurrences are seen in patients younger than 20 years. IS Recurrent tumors retain the histologic and gross characteristics of the original tumor.
In conclusion, CMF of the mastoid is a very rare, benign tumor that can mimic a malignant neoplasm and cause compression ofimportant intracranial structures. Biopsy can provide a definitive histologic diagnosis. In our patient, PET/CT helped to exclude other primary malignancies and the presence of a metastatic lesion while defining the tumor's characteristics. Complete surgical resection is the cornerstone of treatment for cure.
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